New diabetes drug to launch in June

05/2/2005 | Wall Street Journal, The

The U.S. FDA has approved Byetta, known generically as exenatide, to be used in combination with other oral drugs for those with Type 2 diabetes who are not yet dependent on insulin. The drug, a synthetic version of the saliva protein of a Gila monster, is injected twice a day and is designed to stimulate insulin production only when needed by the body. Eli Lilly and Amylin Pharmaceuticals are co-developers of the drug and will co-market it.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN